Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment

Klinische Monatsblatter fur Augenheilkunde

Volumn 232, Issue 4, 2015, Pages 560-563

  Gerding, H ^a,b  

^a Klinik Pallas   (Switzerland)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

aflibercept; age related macular degeneration; anti PIGF; anti VEGF; choroidal neovascularisation; intravitreal injections; ranibizumab; retina

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; LONGITUDINAL STUDY; MACULAR DEGENERATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84928491962     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0035-1545775     Document Type: Article

References (22)

1. Mitchell P., Bressler N., Doan Q. V. et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One: 2014; 9 e101072
2. Gerding H. Ranibizumab treatment in age-related macular degeneration: a meta-analysis of one-year results. Klin Monatsbl Augenheilkd: 2014; 231 427 431
3. Holz F. G., Korobelnik J. F., Lanzetta P. et al. The effects of flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration outcomes of a drug and disease model. Invest Ophthalmol Vis Sci: 2010; 51 405 412
4. Gerding H., Loukopoulos V., Riese J. et al. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Ophthalmol: 2011; 249 653 662
5. Schaal S., Kaplan H. J., Tezel T. H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology: 2008; 115 2199 2205
6. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol: 2012; 96 14 20
7. Heier J. S., Brown D. M., Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age relatred macular degeneration. Ophthalmology: 2013; 119 2537 2548
8. Bakall B., Folk J. C., Boldt H. C. et al. Aflibercept therapy for exsudative age-related macular degeneration resistant to bevacizumab or ranibizumab. Am J Ophthalmol: 2013; 156 15 22
9. Ho V. Y., Yeh S., Olsen T. W. et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Opthalmol: 2013; 156 23 28
10. Yonekawa Y., Andreoli C., Miller J. B. et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol: 2013; 156 29 35
11. Kumar N., Marsiglia M., Mrejen S. et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina: 2013; 33 1605 1612
12. Cho H., Shah C. P., Weber M. et al. Aflibercept for exsudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol: 2013; 97 1032 1035
13. Heussen F. M., Shao Q., Ouyang Y. et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol: 2014; 252 909 915
14. Fassnacht-Riederle H., Becker M., Graf N. et al. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol: 2014; 252 1705 1709
15. Wykoff C. C., Brown D. M., Maldonado M. E. et al. Aflibercept treatment for patients with exsudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol: 2014; 98 951 955
16. Hall L. B., Zebardast N., Huang J. J. et al. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. J Ocul Pharmacol Ther: 2014; 30 346 352
17. Ferrone P. J., Anwar F., Naysan J. et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol: 2014; 98 i17 i21
18. Singh R. P., Srivastava S., Ehlers J. P. et al. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exsudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interims analysis. Br J Ophthalmol: 2014; 98 i22 i27
19. Messenger W. B., Campbell P., Faridi A. et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol: 2014; 98 1205 1207
20. Gharbiya M., Iannetti L., Parisi F. et al. Visual and anatomical outocmes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int: 2014; 2014 273754
21. Grewal D. S., Gill M. K., Sarezky D. et al. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration. Eye: 2014; 28 895 899
22. Martin D. F., Maguire M. G., Fine S. L. et al. Comparison of age-related macular degeneration treatments trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular are-related macular degeneration: two-year results. Ophthalmology: 2012; 119 1388 1398